Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT04775706

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Led by Hanmi Pharmaceutical Company Limited · Updated on 2026-04-28

18

Participants Needed

14

Research Sites

321 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF).

CONDITIONS

Official Title

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men or women aged 18 years or older with short bowel syndrome causing intestinal failure
  • Able to provide signed informed consent and comply with study requirements
  • Diagnosis of short bowel syndrome with the latest intestinal surgery at least 6 months before screening and stable nutritional support needs
  • No planned restorative surgery during the study period
Not Eligible

You will not qualify if you...

  • History of colon cancer
  • History of any other cancers unless disease-free for at least 5 years, except treated skin or cervical cancers
  • History of alcohol or drug abuse within 1 year before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 14 locations

1

Brigham & Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

2

The Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44195

Actively Recruiting

3

UZ Leuven

Leuven, Vlaams Brabant, Belgium, 3000

Actively Recruiting

4

Rigshospitalet Department of Digestive Diseases, Transplantation and General Surgery Section for Intestinal Failure

Copenhagen, Denmark, 2100

Actively Recruiting

5

Hopital Beaujon

Clichy, Clichy, France, 92110

Actively Recruiting

6

Centre Hospitalier Universitaire de Bordeaux

Bordeaux, France, 33000

Actively Recruiting

7

Les Hospices Civils de Lyon

Lyon, France, 69002

Actively Recruiting

8

Centre Hospitalier Universitaire de Nice

Nice, France, 06300

Actively Recruiting

9

Asklepios Klinik St. Georg

Hamburg, Free and Hanseatic City of Hamburg, Germany, 20099

Actively Recruiting

10

Universitätsklinikum Tübingen

Tübingen, Tübingen, Germany, 72076

Actively Recruiting

11

Wojewodzki Specjalistyczny Szpital im. Mikołaja Pirogowa w Łodzi

Lodz, Łódź Voivodeship, Poland, 90-531

Actively Recruiting

12

Samsung Medical Center

Seoul, South Korea, 06351

Actively Recruiting

13

Salford Royal Hospital

Salford, Greater Manchester, United Kingdom, M6 8HD

Actively Recruiting

14

Central Middlesex Hospital

London, United Kingdom, NW10 7NS

Actively Recruiting

Loading map...

Research Team

W

Wooyoung Amy Hong

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects | DecenTrialz